The median age of onset is 40 years, but NMOSD can occur at any age.
Women may be nine times more likely to be impacted versus men.
There is a two- to three-fold higher prevalence in Asian and African American populations.
NMOSD can be difficult to diagnose and is often mistaken for multiple sclerosis (MS).
Specific testing for the antibodies causing the inflammation that led to NMOSD attacks can aid in diagnosis and help determine treatment options. Talk with your doctor about whether a blood test for anti-aquaporin-4 (AQP4-IgG) antibodies may help confirm a diagnosis of NMOSD.
TALK TO YOUR DOCTORIf antibodies against AQP4 are found in your blood, it will confirm you have NMOSD and not MS. AQP4 antibodies are present in up to 80% of NMOSD cases, so testing for this antibody is essential to receiving a diagnosis.
It’s important to talk about NMOSD symptoms and testing, because NMOSD and MS have different treatments. Some MS treatments can make NMOSD symptoms worse, so it’s important to get an accurate diagnosis and explore the right treatment options.
Within one year, 60% of those with NMOSD will have repeat attacks with no NMOSD treatment.
After five years, four out of 10 of those with NMOSD may be legally blind in at least one eye, and two out of 10 may require a walker.
Of those with optic neuritis (or vision challenges), 67% had partial or no recovery following an NMOSD attack.
Below are some resources where you can reach out for support with NMOSD. While these organizations are not owned or controlled by Amgen, and Amgen is not responsible for their content, you may find them helpful.
Patient Health Alliance brings the NMOSD community together through a range of patient advocacy programs and opportunities for connection. These include a 24/7 NMOSD Helpline, hybrid Patient Education Days, virtual Artistry iNMOtion Art & Wellness Workshops, support groups, and more.
DISCOVER RESOURCES
This series brings together the latest research and clinical knowledge on NMOSD, from diagnosis and treatment to what it’s like to live with NMOSD.
LISTEN TO THE PODCAST
This resource has been reviewed by members of SRNA’s Medical and Scientific Council to provide an overview of NMOSD, signs and symptoms, diagnosis, prognosis and more.
VIEW INFORMATION SHEET
These educational videos share information about topics like nerve pain, spasticity, pregnancy, COVID-19 and insurance — all through the lens of NMOSD.
WATCH VIDEOS
This collection of resources, available in 23 languages, includes information on clinical trials, financial support, steroids and seronegative NMOSD.
ACCESS RESOURCES
These questions and answers, available in 23 languages, cover important information about diagnosis, symptoms and available treatments.
FIND IMPORTANT ANSWERS
REFERENCES
1. Ajmera MR, Boscoe A, Mauskopf J, Candrilli SD, Levy M. Evaluation of comorbidities and health care resource use among patients with highly active neuromyelitis optica. J Neurol Sci. 2018;384:96-103. doi:10.1016/j.jns.2017.11.022 2. Neuromyelitis optica spectrum disorder (NMOSD). National Multiple Sclerosis Society. Published 2022. Accessed November 4, 2022. https://www.nationalmssociety.org/What-is-MS/Related-Conditions/Neuromyelitis-Optica-(NMO) 3. Mealy MA, Wingerchuk DM, Greenberg BM, Levy M. Epidemiology of neuromyelitis optica in the United States: A multicenter analysis. Arch Neurol. 2012;69(9):1176-1180. doi:10.1001/archneurol.2012.314 4. Jarius S, Ruprecht K, Wildemann B, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicenter study of 175 patients. J Neuroinflammation. 2012;9(14):1-17. doi:10.1186/1742-2094-9-14 5. Flanagan EP, Cabre P, Weinshenker BG, et al. Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum. Ann Neurol. 2016;79(5):775-783. doi:10.1002/ana.24617 6. Bukhari W, Prain KM, Waters P, et al. Incidence and prevalence of NMOSD in Australia and New Zealand. J Neurol Neurosurg Psychiatry. 2017;0:1-7. doi:10.1136/jnnp-2016-314839 7. Beekman J, Keisler A, Pedraza O, et al. Neuromyelitis optica spectrum disorder: Patient experience and quality of life. Neurol Neuroimmunol Neuroinflamm. 2019;6(4):e580. doi:10.1212/NXI.0000000000000580 8. Borisow N, Mori M, Kuwabara S, Scheel M, Paul F. Diagnosis and treatment of NMO spectrum disorder and MOG-encephalomyelitis. Front Neurol. 2018;9(888):1-15. doi:10.3389/fneur.2018.00888 9. Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85:177-189. doi:10.1212/WNL.0000000000001729 10. Hamid SHM, Whittam D, Mutch K, et al. What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients. J Neurol. 2017;264:2088-2094. doi:10.1007/s00415-017-8596-7 11. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol. 2007;6:805-815. doi:10.1016/S1474-4422(07)70216-8 12. Jiao Y, Fryer JP, Lennon VA, et al. Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology. 2013;81:1197-1204. doi:10.1212/WNL.0b013e3182a6cb5c
People living with NMOSD and their care partners share challenges, triumphs and advocate for their health.
Take a short quiz to help navigate a conversation with your doctor.
